Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
Completed
OBJECTIVES: I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide. II. Determine the toxicity of this drug in these patients.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/23/2005
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland +1 locations
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome